continual production and sustained levels of IFNa. The objective of this study was to investigate lentiviral interferon-alpha (LV-IFNa) activity and LV-mediated gene delivery to the murine bladder.
INTRODUCTION AND OBJECTIVES: Genomic characterization of urothelial bladder cancer (UBC) may help to identify alterations associated with tumor stage, novel therapeutic targets and biomarkers to predict outcomes. In this study, we evaluated genomic alterations of NMIBC, MIBC and metastatic UBC to identify genomic drivers of tumor stage. We also evaluated genomic alterations association with patient outcomes and DNA Damage Repair (DDR) alterations to predict neoadjuvant chemotherapy response.
METHODS: 454 UBC patient tumors were sequenced using next generation sequencing assay. 264 tumors (123 NMIBC, 112 MIBC and 29 metastatic) were chemotherapy naive primary tumors.
RESULTS: Patients whose primary tumors harbored TP53, RB1, TP53/MDM2, and cell cycle pathway alterations more frequently presented with advanced disease whereas those with tumors containing FGFR3, and RTK/RAS/RAF pathway alterations commonly presented with NMIBC (all q<0.001). TP53, RB1, TP53/MDM2, and cell cycle pathway alterations were associated with worse overall (OS) and metastasis free survival (MFS) whereas FGFR3 alterations were associated with more favorable OS and MFS (all q<0.05). RTK/RAS/ RAF pathway alterations were associated with more favorable MFS (q¼0.01). MIBC with DDR wild type, DDR alterations of unknown significance and DDR deleterious alterations had pathologic downstaging rates of 37%, 48% and 81% with platinum-based neoadjuvant chemotherapy (p¼0.013 
MP54-05 PLASTICITY IN THE BIOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER
INTRODUCTION AND OBJECTIVES: Almost two thirds of patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy after cisplatin-based neoadjuvant chemotherapy (NAC) have invasive disease. Biological alterations of these cisplatin-resistant tumors induced by NAC remain largely unstudied.
METHODS: Radical cystectomy (RC) samples were available for gene expression analysis from 133 patients treated with cisplatinbased NAC who had residual invasive disease, of whom 116 had matched pre-NAC samples. In addition, the tumor bed (non-neoplastic scar tissue) of 21 post-NAC RC specimens with complete pathologic response (i.e. pT0N0) was profiled. Unsupervised consensus clustering was performed and the clusters were investigated for their biological and clinical characteristics. H&E staining and immunohistochemistry Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e713 (IHC) on tissue microarrays were used to confirm tissue sampling and the gene expression analysis. RESULTS: Unsupervised consensus clustering yielded four distinct consensus clusters (CC) or subtypes: CC1-Basal, CC2-Luminal, CC3-Immune and CC4-Scar-like. The CC1-Basal and CC2-Luminal subtypes expressed genes consistent with a basal-like (KRT5/ 6, KRT14) and a luminal-like (GATA3, PPARG) phenotype, respectively. The CC3-Immune subtype had the highest immune activity, including T-cell infiltration and checkpoint molecules (CTLA4, CD80). Finally, the CC4-Scar-like profile was consistent with non-neoplastic scar samples, expressing genes associated with wound healing / scarring (MYH11, SHH, CNN1). Approximately the same numbers of pre-NAC basal-and luminal-like samples remained static (CC1 or CC2) with respect to subtype or were highly immune-infiltrated (CC3) in the post-NAC setting. In the post-NAC setting, luminal-like pre-NAC samples were more likely adopt a scar-like character (CC4).
CONCLUSIONS: This study expands our knowledge of cisplatin-resistant MIBC by suggesting molecular subtypes to understand the biology of these tumors. Although these molecular subtypes imply consequences for adjuvant treatments, this ultimately needs to be tested in clinical trials. Meanwhile, Wnt/ b-catenin pathway was reported to be upregulated in human bladder cancer specimens. However, no clear evidence has been reported that the pathway is directly involved in proliferation of bladder cancer cells. In this study, we assessed the involvement of Wnt/b-catenin pathway in proliferation of bladder cancer cells using organoid culture.
METHODS: Organoids from bladder cancer cell lines RT4 (luminal phenotype) and 5637 (basal phenotype) were generated by an aggregation method. A partial-digestion method was applied to prepare organoids directly from patient bladder cancer specimens. Wnt/b-catenin pathway was activated by using a small molecule CHIR99021 (GSK3 inhibitor, Wnt activator) and inhibited by siRNA against b-catenin. Activation of Wnt/b-catenin pathway was confirmed by upregulated AXIN2 mRNA expression and translocation of b-catenin into nucleus. Proliferation of cancer cells were evaluated by growth assay under microscope and ATP viability assay. Differentiation status of organoids over growth was characterized by qRT-PCR and western blot.
RESULTS: CHIR99021 inhibited proliferation of cell lines in conventional monolayer adherent culture, but promoted proliferation in three-dimensional organoid culture with activation of Wnt/b-catenin pathway. Enhanced proliferation of cancer cells with activation of Wnt/bcatenin pathway by CHIR99021 was also observed in patient-derived organoids. When b-catenin was knockdowned in cell lines, the growth of organoids was significantly suppressed. Cytokeratin 20, a terminal differentiation marker, was less expressed over CHIR99021-enhanced cell proliferation.
CONCLUSIONS: We showed for the first time that Wnt/b-catenin pathway was directly involved in proliferation of bladder cancer cells, suggesting that Wnt/b-catenin pathway may be a potential target for the treatment of a subset of bladder cancer. The above finding could not be observed when the same cells were grown in conventional twodimensional adherent cultures, providing a concrete example of why organoid culture is important for cancer research.
Source of
Funding: The Greenberg Bladder Cancer Institute Research Grant and the Urology Care Foundation
MP54-07 HEPATOCYTE GROWTH FACTOR RECEPTOR/C-MET IS ASSOCIATED WITH MALIGNANT AGGRESSIVENESS VIA REGULATION OF CYCLOOXYGENASE-2, HEMEOXYGENASE-1, AND PROGRAMMED DEATH LIGAND 1 IN PATIENTS WITH BLADDER CANCER
Yuichiro Nakamura*, Yasuyoshi Miyata, Kyohei Araki, Takuji Yasuda, Tomohiro Matsuo, Kojiro Ohba, Bungo Furusato, Junya Fukuoka, Hideki Sakai, Nagasaki, Japan INTRODUCTION AND OBJECTIVES: Hepatocyte growth factor receptor/c-Met is a receptor tyrosine kinase that plays crucial roles in tumor growth, invasion, and metastasis in malignancies, including bladder cancer (BC). c-Met displays multiple functions via regulation of cyclooxygenase-2 (COX-2), hemeoxygenase-1 (HO-1) and programmed death ligand 1 (PD-L1) in various cancer types. However, the pathological significance of c-Met signaling system in BC is questionable. Here we investigate the pathological role of c-Met and phosphorylated c-Met in patients with BC.
METHODS: Expressions of c-Met and two tyrosine residues of c-Met (using phosphorylation site-specific antibodies for pY1234/ pY1235 and pY1349) were immunohistochemically examined and their correlation with COX-2, HO-1, and PD-L1 was investigated in 185 BC specimens. The relationship between expressions of c-Met and phosphorylated c-Met and clinicopathological features and expressions of COX-2, HO-1, and PD-L1 was analyzed.
RESULTS: Expressions of c-Met, pY1234/1235 c-Met, and pY1349 c-Met were associated with pT stage (P ¼ 0.013, P ¼ 0.002, and P < 0.001, respectively). In contrast, expressions of pY1234/1235 c-Met and pY1349 c-Met, but not c-Met, were associated with metastasis (P ¼ 0.003 and P ¼ 0.006, respectively). c-Met and pY1234/1235 c-Met correlated with PD-L1 (P < 0.001) and COX-2 (P ¼ 0.011), respectively, while a significant correlation was observed between pY1349 c-Met and COX-2, HO-1, and PD-L1 (P ¼ 0.006, P ¼ 0.002, and P < 0.001, respectively). The multi-variate analysis model including grade, pT stage, and metastasis demonstrated the independent correlation between c-Met and PD-L1 (odds ratio, [OR] ¼ 3.52, P < 0.001) as well as pY1349 c-Met and COX-2 (OR ¼ 2.35, P ¼ 0.015), HO-1 (OR ¼ 3.83, P ¼ 0.031), and PD-L1 (OR ¼ 3.33, P < 0.001). Among COX-2, HO-1, PD-L1, positive correlation was observed only between COX-2 and PD-L (P < 0.001). The multivariate analysis model including all pathological features and these molecules demonstrated that pY1349 c-Met and COX-2 were independently associated with PD-L1 expression (OR ¼ 5.54, P ¼ 0.002 and OR ¼ 4.33, P ¼ 0.037, respectively).
CONCLUSIONS: The expression of pY1349 c-Met was closely associated with malignant aggressiveness via regulation of COX-2, HO-1, and PD-L1. In addition, PD-L1 expression may be upregulated via the expression of COX-2 and c-Met by complex mechanisms.
Source of Funding: none
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